Romurtide, a synthetic muramyl dipeptide derivative, accelerates peripheral platelet recovery in nonhuman primate chemotherapy model.
We investigated the therapeutic effects of romurtide, a synthetic muramyl dipeptide derivative, on experimental thrombocytopenia induced by carboplatin in cynomolgus monkeys. A prolonged thrombocytopenia due to a severe myelosuppression was induced by carboplatin. Romurtide given subcutaneously elevated significantly the peripheral platelet counts during both early initiation and later recovery phase of thrombocytopenia, thereby shortening the time required for recovery to a normal platelet level and the duration of thrombocytopenia. An oral administration of romurtide was also found to have a similar therapeutic efficacy to subcutaneous administration. These results demonstrated a possible therapeutic potential of romurtide in the management of thrombocytopenia associated with myelosuppression.
Namba
K
K
New Product Research Laboratories 1, Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan.
Nitanai
H
H
Otani
T
T
Azuma
I
I
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D000284:Administration, Oral; D000818:Animals; D001792:Blood Platelets / Q000166:cytology; D016190:Carboplatin / Q000633:toxicity; D002455:Cell Division / Q000187:drug effects; D004195:Disease Models, Animal; D005260:Female; D008252:Macaca fascicularis; D013921:Thrombocytopenia / Q000139:chemically induced / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D000119:Acetylmuramyl-Alanyl-Isoglutamine; D016190:Carboplatin; C036866:romurtide